INCY | Complete Incyte Corp. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.
Price (EUR)69.88 Today's Change0.540 / 0.78% Shares traded724.00 1 Year change+25.68% Beta-- Data delayed at least 15 minutes, as of Jan 29 2025 07:06 GMT. Participate in the 2025 Stockpicking Contest Long or short five stocks and compete to have the highest return by the end of the...
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte(Nasdaq:INCY) today reports 2024 first quarter financial results, and provides a status update on the Company’s clinical development portfolio. "In the first quarter of 2024, total revenues grew 9% year-over-year driven by patient demand growth i...
3 Non-GAAP selling, general and administrative expenses exclude the cost of stock-based compensation and asset impairments. 4 Non-GAAP loss on change in fair value of acquisition-related contingent consideration is null. Cost of product revenues GAAP and Non-GAAP cost of prod...
Incyte today reports 2022 fourth quarter financial results, provides 2023 financial guidance and provides a status update on the Company’ s clinical development portfolio. Opzelura has now become the market share leader among branded agents for new atop
recommended for you about incy stock symbol last price % chg 1d 5d 1m 6m 1y 5y 10y market cap pe yield rev growth (yoy) short interest prev. close compare to peers more on incy related stocks symbol last price % chg incy incy - - 1d 5d 1m 6m 1y 5y 10y compare trending analysis ...
Incyte (Nasdaq:INCY) today reports 2022 second quarter financial results, and provides a status update on the Company’s clinical development portfolio.
Stock Price $74.12 Change 0.52% Volume 1,269,830 Incyte Corp Ltd is a biopharmaceutical company. It discovers, develops and commercializes proprietary small molecule drugs to treat serious unmet medical needs. Request Video of INCY Already a member? Sign in here. Past Month Leading Peers DWTX ...
3 Non-GAAP selling, general and administrative expenses exclude the cost of stock-based compensation and legal settlements. 4 Non-GAAP loss on change in fair value of acquisition-related contingent consideration is null. Research and development expenses GAAP and Non-GAAP research and de...